Skip to main
MBOT
MBOT logo

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. presents a strong outlook due to its LIBERTY Endovascular Robotic System, which is designed to enhance procedure efficiency while significantly lowering costs and improving the quality of care in endovascular procedures. The company's estimated market value has reached $843 million, driven by a robust discounted cash flow-based asset value of $781 million for the LIBERTY System, indicating positive investor sentiment and confidence in future growth. Additionally, the firm has successfully raised sufficient capital to support its commercial strategy, and a remarkable 92% relative reduction in radiation exposure enhances the technology's appeal to healthcare providers.

Bears say

Microbot Medical Inc faces significant challenges that may hinder its growth potential, primarily due to slower than anticipated commercial uptake influenced by market size, penetration rates, and competitive pressures. Additionally, the company may encounter financial instability stemming from potential dilution risks, which could adversely affect shareholder value. These fundamental concerns contribute to a negative outlook on the company's stock performance.

Microbot Medical (MBOT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.